[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-337531-105":59,"doc-detail-337531-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","a-pilot-study-on-patient-specific-computational-forecasting-of-prostate-cancer-growth-during-active-surveillance-research","A Pilot Study on Patient-specific Computational Forecasting of Prostate Cancer Growth during Active Surveillance - Research","","Active surveillance offers a management option for newly diagnosed prostate cancer, but existing protocols often detect progression only through population-based monitoring, limiting patient-specific planning and potentially delaying intervention. This pilot study tests patient-personalized computational forecasts of tumor growth using an imaging-informed spatiotemporal biomechanistic model driven by longitudinal mpMRI (T2-weighted and ADC maps). Results quantify global tumor burden with high concordance (0.93–0.99, n=7), derive a high-risk biomarker, and build a risk classifier achieving AUC 0.83. Coupled forecasting enables earlier identification of progression by more than one year.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/a-pilot-study-on-patient-specific-computational-forecasting-of-prostate-cancer-growth-during-active-surveillance-research/337531/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/a-pilot-study-on-patient-specific-computational-forecasting-of-prostate-cancer-growth-during-active-surveillance-research/337531.png","ImageObject",300,407,{"name":92,"@type":93},"Finn","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-16","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does this pilot study address in active surveillance for prostate cancer?","Question",{"text":112,"@type":113},"It targets limitations of current AS protocols that rely on population-based monitoring, which can restrict individualized plan design and delay detection of progression.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What data and modeling approach are used to generate the forecasts?",{"text":117,"@type":113},"Forecasts are produced with an imaging-informed spatiotemporal biomechanistic model using patient-specific longitudinal mpMRI inputs, including T2-weighted MRI and apparent diffusion coefficient maps.",{"name":119,"@type":110,"acceptedAnswer":120},"What performance results and biomarkers does the study report?",{"text":121,"@type":113},"The model forecasts global tumor burden with concordance correlation coefficients from 0.93 to 0.99 across seven patients. It also identifies a model-based biomarker of higher-risk disease and uses it to form a logistic regression classifier with AUC 0.83.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},337531,1792184098,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},34359740700684,"https://ap-avatar.wpscdn.com/avatar/1f400023980c374ae676?_k=1777273430885731487","RESEARCH ARTICLE  [https://doi.org/10.1158/2767-9764.CRC-23-0449](https://doi.org/10.1158/2767-9764.CRC-23-0449)  OPEN ACCESS  \nA Pilot Study on Patient-speciﬁc Computational Forecasting of Prostate Cancer Growth during Active Surveillance Using an Imaging-informed Biomechanistic Model  \nGuillermo Lorenzo1 , 2 , Jon S. Heiselman3 , 4 , Michael A. Liss5 , Michael I. Miga3 , 6 , 7 ,  \nHector Gomez8 , Thomas E. Yankeelov2 , 9 , 10 , Alessandro Reali1 , and Thomas J. R. Hughes2  \nCheck for updates  \nABSTRACT  \nActive surveillance (AS) is a suitable management option for newly diagnosed prostate cancer, which usually presents low to intermediate clinical risk. Patients enrolled in AS have their tumor monitored via longitudinal multiparametric MRI (mpMRI), PSA tests, and biopsies. Hence, treatment is prescribed when these tests identify progression to higher-risk prostate cancer. However, current AS protocols rely on detecting tumor progression through direct observation according to population-based monitoring strategies. This approach limits the design of patient-specific AS plans and may delay the detection of tumor progression. Here, we present a pilot study to address these issues by leveraging personalized computational predictions of prostate cancer growth. Our forecasts are obtained with aspatiotemporal biomechanistic model informed by patient-specific longitudinal mpMRI data (T2-weighted MRI and apparent diffusion coefficient maps from diffusion-weighted MRI). Our results show that our technology can represent and forecast the global tumor burden for individual patients,  \nachieving concordance correlation coefficients from 0.93 to 0.99 across our cohort (n = 7). In addition, we identify a model-based biomarker of higherrisk prostate cancer: the mean proliferation activity of the tumor (P = 0.041) . Using logistic regression, we construct a prostate cancer risk classifier based on this biomarker that achievesan area under the ROC curve of  \n0.83. We further show that coupling our tumor forecasts with this prostate cancer risk classifier enables the early identification of prostate cancer progression to higher-risk disease by more than 1 year. Thus, we posit that our predictive technology constitutes a promising clinical decision-making tool to design personalized AS plans for patients with prostate cancer.  \nSignificance: Personalization of a biomechanistic model of prostate cancer with mpMRI data enables the prediction of tumor progression, thereby showing promise to guide clinical decision-making during AS for each individual patient.  \nIntroduction  \nProstate cancer is the second most common type of cancer and the fifth leading cause of cancer death among men worldwide (1) . The clinical management of prostate cancer relies on two key strategies (2): regular screening and patient triage into risk groups. Regular screening of prostate cancer is performed in men over 50 and consists of a digital rectal exam and the measurement of the serum level of the PSA. If the results of these two tests are suggestive of  \n1 Department of Civil Engineering and Architecture, University of Pavia, Pavia, Italy.  \n2 Oden Institute for Computational Engineering and Sciences, The University of Texas at Austin, Austin, Texas. 3 Department of Biomedical Engineering, Vanderbilt University, Nashville, Tennessee. 4 Department of Surgery, Memorial  \nSloan-Kettering Cancer Center, New York, New York. 5 Department of Urology, The University of Texas Health Science Center at San Antonio, San Antonio, Texas.  \n6Vanderbilt Institute for Surgery and Engineering, Vanderbilt University, Nashville, Tennessee. 7 Department of Neurological Surgery, Radiology, and Otolaryngology-Head and Neck Surgery, Vanderbilt University Medical Center, Nashville, Tennessee. 8 School of Mechanical Engineering, Weldon School of Biomedical Engineering, and Purdue Institute for Cancer Research, Purdue  \nprostate cancer, then a multiparametric MRI (mpMRI) scan will usually be p","cbCaib9WJIilvDh3","https://ap.wps.com/l/cbCaib9WJIilvDh3","pdf",13581270,17,"English","# Abstract\n# Significance\n# Introduction","[{\"question\":\"What problem does this pilot study address in active surveillance for prostate cancer?\",\"answer\":\"It targets limitations of current AS protocols that rely on population-based monitoring, which can restrict individualized plan design and delay detection of progression.\"},{\"question\":\"What data and modeling approach are used to generate the forecasts?\",\"answer\":\"Forecasts are produced with an imaging-informed spatiotemporal biomechanistic model using patient-specific longitudinal mpMRI inputs, including T2-weighted MRI and apparent diffusion coefficient maps.\"},{\"question\":\"What performance results and biomarkers does the study report?\",\"answer\":\"The model forecasts global tumor burden with concordance correlation coefficients from 0.93 to 0.99 across seven patients. It also identifies a model-based biomarker of higher-risk disease and uses it to form a logistic regression classifier with AUC 0.83.\"}]","A Pilot Study on Patient-specific Computational Forecasting of Prostate Cancer Growth during Active Surveillance - Research | PDF",1790019490,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2f9128a3a436551f1523a1cb8a3d5ec1.webp",983,1263,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c4b4f88bbe515c8ba103740754f5eeb2.webp",982,1262,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1179c6835fc9be1c4e0b64d6059d026e.webp",981,1261,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8d2e89689b56c3c0d3d73c4771ad4a4d.webp",980,1259]